Use of GLP-1 receptor agonists in patients with T2DM and chronic kidney disease

被引：2

作者：

Aldrich, Sarah ^{[1
]}

Ashjian, Emily ^{[2
]}

机构：

[1] Univ Toledo, Coll Pharm & Pharmaceut Sci, 2801 W Bancroft St, Toledo, OH 43606 USA

[2] Univ Michigan, Coll Pharm, 428 Church St, Ann Arbor, MI 48109 USA

来源：

NURSE PRACTITIONER | 2019年 / 44卷 / 03期

关键词：

chronic kidney disease; diabetes; dialysis; dulaglutide; end-stage renal disease; exenatide; glucagon-like peptide-1 receptor agonist; liraglutide; lixisenatide; semaglutide; type 2 diabetes mellitus; CARDIOVASCULAR OUTCOMES; TYPE-2; RISK; EXENATIDE; SAFETY; PHARMACOKINETICS; LIXISENATIDE; TOLERABILITY; DULAGLUTIDE; MORTALITY;

D O I：

10.1097/01.NPR.0000553396.65976.bb

中图分类号：

R47 [护理学];

学科分类号：

1011 ;

摘要：

Diabetes mellitus is the leading cause of chronic kidney disease (CKD) in the US. An increasing number of glucagon-like peptide-1 receptor agonists are available for diabetes management. Differences between medications in this class, as well as limited data on patients with CKD, underscore the importance of a patient-centered approach to care.

引用

页码：20 / 28

页数：9

共 45 条

[1] Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019 [J].

Cefalu, William T. ;

Berg, Erika Gebel ;

Saraco, Mindy ;

Petersen, Matthew P. ;

Uelmen, Sacha ;

Robinson, Shamera .

DIABETES CARE, 2019, 42 :S124-S138

[2]

[Anonymous], 2013, KIDNEY INT SUPPL, V3, P1, DOI DOI 10.1038/KISUP.2012.73

[3]

[Anonymous], 2015, BYETT R

[4]

[Anonymous], 2017, BLACK TRACK US ANN R

[5]

[Anonymous], 2018, TRUL R

[6]

[Anonymous], KIDN DIS STAT US

[7]

[Anonymous], 2012, BYD R

[8]

[Anonymous], 2017, VICT R

[9]

[Anonymous], 2016, ADL R

[10]

[Anonymous], 2017, OZ R

← 1 2 3 4 5 →